activin A receptor type 1BGenealiases: ACTRIB · ACVRLK4 · ALK4 · SKR2
Q-omics provides the consensus-scored ACVR1B profile across patient tissues and cancer cell-line models. ACVR1B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ACVR1B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ACVR1B RNA expression shows 20,465 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where ACVR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACVR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACVR1B survival associations across molecular data types. ACVR1B RNA expression shows survival associations in the most cancer types (16), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACVR1B RNA expression–survival associations across cancer types. High ACVR1B expression shows unfavorable associations in LIHC, UCEC, MESO, HNSC and SKCM, but favorable associations in UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ACVR1B RNA expression.
This table summarizes ACVR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACVR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACVR1B shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in STAD, UCEC and BLCA. The KIRC box plot shows higher ACVR1B RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with ACVR1B in patient tissues and cancer cell lines. In patient samples, ACVR1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACVR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
